Valuation: Cartesian Therapeutics, Inc.

Market Cap 304M 260M 243M 223M 418M 29.06B 424M 2.88B 1.12B 14.6B 1.14B 1.12B 48.29B P/E 2026 *
-3.36x
P/E 2027 * -2.42x
Enterprise Value 163M 139M 130M 119M 224M 15.57B 227M 1.54B 601M 7.82B 611M 598M 25.88B EV / Sales 2026 *
429x
EV / Sales 2027 * 56.3x
Free-Float
47.87%
Yield 2026 *
-
Yield 2027 * -
1 day-1.86%
1 week+13.57%
Current month+28.72%
1 month+26.77%
3 months+48.74%
6 months+43.84%
Current year+39.25%
1 week 9
Extreme 9
10.87
1 month 7.27
Extreme 7.27
10.87
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11.38
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap.
1/6/26 Sell

Chief Technology Officer

3,573 0.0137%
1/6/26 Sell

Chief Executive Officer

23,766 0.0914%
1/6/26 Sell

Chief Financial Officer

10,591 0.0407%
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+13.57%-10.60% - 304M
-3.00%+2.27%+73.26%+113.08% 72.12B
+1.90%+23.53%+59.48%+94.94% 65.85B
+5.12%+25.22%+5.13%-5.23% 29.28B
+0.55%+1.64%-4.63%+469.35% 27.47B
-3.96%+6.24%+47.36%+9.96% 26.7B
+0.47%+6.12%+37.01%-16.17% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
-2.04%+1.24%+12.60%+557.14% 16.4B
+0.73%+5.54%+39.99%+148.64% 13.4B
Average +0.02%+8.88%+51.09%+195.63% 28.98B
Weighted average by Cap. -0.01%+9.49%+57.10%+156.49%

Financials

2026 *2027 *
Net sales 379K 325K 304K 278K 522K 36.29M 529K 3.59M 1.4M 18.23M 1.42M 1.39M 60.29M 250K 214K 200K 183K 344K 23.92M 349K 2.37M 923K 12.02M 939K 918K 39.74M
Net income -87.44M -74.9M -70.09M -64.15M -120M -8.37B -122M -828M -323M -4.2B -328M -321M -13.9B -143M -122M -115M -105M -197M -13.67B -199M -1.35B -528M -6.87B -537M -525M -22.72B
Net Debt -141M -121M -113M -103M -194M -13.49B -197M -1.34B -521M -6.78B -529M -518M -22.42B -290M -248M -232M -213M -399M -27.72B -404M -2.74B -1.07B -13.92B -1.09B -1.06B -46.06B
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
26-08-21 US$10.04 -1.86% 163,914
26-08-20 US$10.23 -2.48% 134,750
26-08-19 US$10.49 +14.02% 482,468
26-08-18 US$9.200 +0.22% 138,352
26-08-17 US$9.180 +3.85% 108,703
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.04USD
Average target price
34.57USD
Spread / Average Target
+244.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNAC Stock